Asymmetric dimethylarginine (ADMA) has evolved as an important regulator of nitric oxide (NO) synthesis in recent years. Elevated levels of ADMA have been reported in many conditions associated with a high cardiovascular risk. Moreover, ADMA is a biomarker for major cardiovascular events and mortality in cohorts with high, intermediate and low overall cardiovascular risk. Discrepant data have been reported on cardiovascular risk in people with and without diabetes mellitus, and the association of ADMA with diabetes mellitus per se has also remained controversial, possibly relating to type and stage of diabetes. Clinical and experimental data suggest that there is a multifaceted link between ADMA and insulin metabolism and action on one hand, and ADMA and glucose utilisation on the other. This interplay may be regulated by the enzyme involved in the metabolic degradation of ADMA, dimethylarginine dimethylaminohydrolase (DDAH). Recent data from prospective clinical studies suggest that whilst ADMA may be a marker for total mortality in patients without diabetes, elevated ADMA may exert beneficial effects in patients with diabetes. In this respect, ADMA could serve as a re-coupling agent overcoming endothelial nitric oxide synthase (eNOS) uncoupling in patients with diabetes. Anticipated advances in clinical and experimental investigation will help us to better understand this complex interrelationship between diabetes, eNOS, DDAH and ADMA.
Introduction
Endothelium-mediated regulation of vascular tone and vascular structure has been a fascinating topic in cardiovascular medicine since the first discovery, in 1980, by Robert Furchgott and his co-workers that the vascular relaxation in response to acetylcholine critically depends upon the presence of an intact vascular endothelium. 1, 2 We later learned that nitric oxide (NO) is the elusive mediator (previously named endothelium-derived relaxing factor and released by healthy endothelium) that causes vascular dilatation. 3 Since then, evidence has accumulated regarding the intriguing fact that mechanical injury and, much more relevantly from a pathophysiological perspective, biochemical injury to the endothelium may be a cause of impaired NO-dependent vascular function. 4 This phenomenon, called endothelial dysfunction, is an early event on the long road towards atherosclerotic vascular disease. Endothelial dysfunction has been found as early as in the early adolescent period, in adults generation, during its diffusion from endothelial cells to its target cells in the subendothelial layers of the vascular wall or to the cells of the flowing blood, or within the subsequent signalling cascade that links NO to its cellular functions ( Figure 1 ). Thus, genetic polymorphisms of the endothelial nitric oxide synthase (eNOS) gene, 5 defects in gene expression of eNOS, 6 impaired coupling of endothelial G-protein coupled receptors to nitric oxide synthase (NOS), 7 reduced NOS enzyme activity, 8 and enhanced inactivation of NO by reactive oxygen species in the vascular wall 9, 10 have all been shown to be involved in the phenomenon called endothelial dysfunction under varying conditions. One interesting observation that was repeatedly reported by different groups of investigators has been the fact that supplementation with L-arginine was able, under in vivo conditions, to improve endothelial dysfunction, [11] [12] [13] although enzyme biochemistry strongly suggested that the enzyme is saturated with substrate. 14 This observation was named the 'L-arginine paradox', 15 and it stipulated research into possible molecular mechanisms that might explain it. The discovery, in 1992, by Vallance and co-workers that the naturally occurring, methylated L-arginine analogue asymmetric dimethylarginine (ADMA) acts as a competitive inhibitor of NO synthase 16 finally resolved this paradox. Low circulating concentrations of endogenous methylarginines such as ADMA or L-monomethylarginine (L-NMMA) competitively inhibit eNOS at physiological concentrations and result a rightwards shift of the concentration-response curve of L-arginine. 17 The pathophysiological relevance of this interaction is supported by the low inhibitory constants of ADMA and L-NMMA for eNOS, i.e. K i values of 0.9 and 0.4 µM, respectively, 18, 19 which are within their (patho-) physiological concentration ranges.
ADMA has been shown to be a marker of endothelial dysfunction in humans. 20 It is increased early enough during atherogenesis to be eligible as a causative factor; 13 even small changes in extracellular fluid have been shown to correspond to large enough changes in intracellular ADMA concentration that can affect NOS activity. 19 ADMA is metabolised by dimethylarginine dimethylaminohydrolase (DDAH) to L-citrulline and dimethylamine. In humans two isoforms of DDAH (DDAH-1 and DDAH-2) are found with distinct but overlapping tissue distribution. 21 In this review we summarise recent data on the role of ADMA in vascular disease with a specific focus on its potential contribution to vascular changes occurring in diabetes mellitus.
Role of the endothelium in diabetes mellitus
It is widely recognised that patients with diabetes mellitus are at high risk of developing micro-and macroangiopathic complications, and the diabetic state is considered a major cardiovascular risk factor. 22 Very soon after the discovery that endothelium-dependent vasodilation is impaired in atherosclerosis and hypercholesterolaemia, [23] [24] [25] it was reported that endothelial dysfunction can also be observed in blood vessels from diabetic animals. 26 This was confirmed in studies in human subjects with diabetes. Patients with diabetes mellitus, Abbreviations: ADP, adenosine diphosphate; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; NO, nitric oxide; cGMP, cyclic guanosine monophosphate. Numbers in circles relate to possible mechanisms for endothelial dysfunction (see the text): 1, polymorphisms in the eNOS gene; 2, impaired NOS gene expression; 3, impaired signalling of G-protein coupled receptors; 4, reduced enzyme activity of NOS, possibly by the endogenous NOS inhibitor, ADMA; impaired cellular uptake of L-arginine due to inhibition of the y+ amino acid transporter by ADMA and SDMA; 5, oxidative degradation of NO by superoxide radicals.
but also subjects with reduced insulin sensitivity, showed impaired endothelium-dependent vasodilation of the microand macrovasculature compared with healthy controls. [27] [28] [29] [30] [31] [32] [33] [34] Endothelium-independent vasodilation, on the other hand, was similar among patients with diabetes mellitus and controls in all of these studies, suggesting that impaired glucose tolerance and diabetes mellitus specifically cause impaired NO production or NO bioavailability in the endothelium. Metabolic abnormalities found in diabetes such as hyperinsulinaemia, hyperglycaemia, and dyslipidaemia along with oxidative stress were all shown to contribute to endothelial dysfunction. [35] [36] [37] [38] [39] In turn, endothelial dysfunction was also shown to be present in very early stages of atherosclerosis, 40 suggesting, but not proving, that endothelial dysfunction may be a pathophysiological link explaining the high rate of vascular complications in diabetes.
However, there is some evidence that endothelial dysfunction precedes the development of diabetes and may even contribute to the development of insulin resistance. In prospective studies, haemostatic and inflammatory markers of endothelial dysfunction were shown to be independent predictors for new-onset diabetes mellitus. [41] [42] [43] [44] [45] Laakso et al. 46 demonstrated in obese patients that reduced insulinstimulated leg blood flow, a marker of endothelial dysfunction, leads to reduced glucose uptake in the skeletal muscle and may therefore promote insulin resistance. However, as insulin-stimulated total limb blood flow takes several hours to reach its maximum increase, there has been an argument over whether this observation is relevant at all. 47 Capillary recruitment, on the other hand, was shown to be an early effect of insulin. 48 It precedes insulin-stimulated glucose uptake into skeletal muscle, indicating a potentially crucial role in glucose homeostasis. Since both of these effects of insulin are mediated by NO, endothelial dysfunction may lead to attenuated glucose uptake in insulin-sensitive tissues, hyperglycaemia, and may ultimately contribute to the development of diabetes. 47, 48 Furthermore, transendothelial transport of insulin was demonstrated in dogs to be the time-limiting factor for insulin action in insulin-sensitive tissues, pointing to another possible mechanism by which endothelial dysfunction may add to reduced insulin sensitivity, namely by attenuated transendothelial transport of insulin to its effectors. 49 Finally, it has recently been hypothesized that beta cell ischaemia, due to endothelial dysfunction and reduced perfusion of pancreatic islets, might cause type 2 diabetes mellitus. 50 An experimental proof of this interesting hypothesis, however, is still lacking.
In summary, there is a complex reciprocal interrelationship between glucose metabolism, insulin sensitivity and diabetes on the one hand, and endothelium-dependent, NOmediated vascular function on the other hand. 51 This interrelation ship, which is far from being fully understood to date, has been enriched by another regulatory, and regulated, molecule, which, according to current understanding, adds another level of complexity. This molecule is ADMA, an endogenous inhibitor of NOSs.
ADMA as a regulator of vascular function and dysfunction
The possible regulatory role of ADMA and related methylarginine compounds for NOS activity has been an area of intense research in recent years. However, these endogenous inhibitors of NOS are not the only known regulators of eNOS substrate availability: arginases compete with NOS for the same substrate, i.e. L-arginine. Even though the K m of mammalian arginases I and II for L-arginine is high (ranging from 2-20 mM), their turnover rates are more than 1,000 times faster than that of eNOS (for a sophisticated review on the role of arginases for NO biosynthesis, see Wu and Morris 52 ). Finally, circulating L-arginine is not directly accessible to eNOS. It has to be shuttled through the lipid membrane of the endothelial cell by y + -type cationic amino acid transporters such as SLC7a1 and SLC7a2. 53 Whilst these transporters have to accomplish the influx of NOS substrate into the cell, they also have to maintain the contemporaneous efflux of ADMA and L-NMMA out of the endothelial cell. Interestingly, these amino acid transporters also mediate the efflux of symmetric dimethylarginine (SDMA), which by itself is not an inhibitor of NOS activity. Nonetheless, SDMA was shown to reduce cellular L-arginine uptake, illustrating the important role of these various endogenous methylated L-arginine analogues for endothelial NO production and vascular homeostasis.
Two isoforms of the enzyme degrading ADMA and L-NMMA, DDAH-1 and -2, have been characterized in recent years, which have a distinct tissue distribution and appear to be differentially regulated. Animal models of DDAH-1 overexpression and knockdown have provided evidence for the role of this enzyme in regulating vascular tone. Both deleting the DDAH-1 gene in mice and inhibiting its activity through DDAH-specific inhibitors caused endothelial dysfunction, increased systemic vascular resistance and elevated systemic and pulmonary blood pressure. 54 We recently reported the first data from a vascular endothelialspecific DDAH-1-deficient mouse strain; 55 these mice have greatly reduced DDAH expression in kidney, lung, brain and liver, a significantly elevated ADMA concentration in plasma, increased blood pressure and impaired endothelial function. In contrast, mice transgenic for human (h)DDAH-1 demonstrated high activity of DDAH-1 in heart tissue and the endothelium, 56 a systolic blood pressure lowered by as much as 13 mmHg, as well as diminished systemic vascular resistance and cardiac contractility. 57 Moreover, overexpression of hDDAH-1 inhibited asymmetric dimethylarginineinduced endothelial dysfunction in the cerebral circulation. 58 Silencing of DDAH-2 by RNAi in rats markedly reduced NO bioavailability and distorted sensitivity of mesenteric resistance vessels (MRVs) to acetylcholine, whilst circulating ADMA concentration remained unaffected by this. 59 ADMA infused in mice elevated blood pressure and caused subclinical atherosclerosis in coronary blood vessels (media thickening and perivascular fibrosis) which was completely blunted in littermates overexpressing DDAH-2. 60 When the same mice were challenged with a high-fat diet (HFD), the transgenic siblings were protected from insulin resistance during intraperitoneal glucose tolerance test (IGTT) and intraperitoneal insulin tolerance test (IITT) (Hasegawa et al.; personal communication, 2008) . Furthermore, HFD selectively decreased islet ATP content and increased islet uncoupling protein-2 (UCP2) expression in wild-type mice. These data raise hope that activation of the DDAH-2 gene may arise as a novel therapeutic option to ameliorate insulin secretion and sensitivity in the metabolic syndrome.
There is some evidence for a protective role of DDAH-2 in humans. In the population-based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) Augsburg study, we found that two single-nucleotide polymorphisms in the DDAH-2 promoter region are associated with an increased prevalence of hypertension. 61 In line with its predominantly vascular (endothelial) expression profile, these data pinpoint to a peculiar role of DDAH-2 within the vascular system which deserves further investigation.
ADMA and cardiovascular disease
Elevated plasma concentrations of ADMA have been reported in a variety of cardiovascular diseases as well as in patient populations with almost any traditional and emerging cardiovascular risk factor, suggesting that ADMA is an early marker of atherosclerotic vascular disease (for an overview, cf. Böger 62 ). Moreover, prospective clinical studies have convincingly shown that high ADMA plasma levels are associated with an increased incidence of major cardiovascular events and with total mortality. This was found in high-risk populations such as haemodialysis patients, 63 in patients with multi-organ failure treated on a multidisciplinary intensive care unit, 64 and in patients after acute myocardial infarction. 65 ADMA was also reported to be a risk marker for cardiovascular disease and mortality in medium-risk populations such as patients with stable coronary artery disease, [66] [67] [68] chronic heart failure, 69 peripheral arterial disease 70 and type 2 diabetes mellitus. 71 The relevance of ADMA as a prospective risk marker has been less clear for the general population, as a lower incidence of severe cardiovascular events and mortality in lowrisk cohorts necessitates huge patient numbers and very long follow-up periods. 72 Nonetheless, two small population-based cohorts found a significant association between elevated ADMA levels and cardiovascular disease events and death, both in non-smoking men. 73, 74 In the Framingham Offspring cohort, a large population-based sample comprising 3,320 subjects of both sexes, we recently reported a significant positive association of ADMA and all-cause mortality, 75 whilst the association of ADMA with cardiovascular disease events was not significant after a mean followup of 24 years. Investigators of the Women in Gothenburg Study, 76 which consists of a cohort of 880 women from the healthy population, found a significant association of ADMA with total mortality and with cardiovascular disease events after as many as 24 years of follow up. Interestingly, their Kaplan-Meier analysis demonstrated that the curves for women with high or low ADMA began to separate as late as 13 years after the initial blood sampling, supporting the view that more prospective cohorts with long follow up will be needed to ascertain the role of ADMA as a risk factor in the general population.
ADMA and diabetes mellitus
Insulin-mediated glucose uptake as well as the reactivity of vessels in insulin-sensitive tissues are modulated by NO generated in the endothelium. 77 Pharmacological inhibition of NO synthesis by N-monomethyl-L-arginine methylester (L-NAME) as well as genetic disruption of NO synthesis both aggravate insulin resistance by reducing microvascular recruitment or muscle glucose uptake in response to insulin. 47 Several studies reported elevated plasma ADMA concentrations in type 1 or type 2 diabetes mellitus. ADMA increases even before the development of vascular complications, as shown in 40 patients with uncomplicated type 1 diabetes mellitus. 78 An association between increased plasma ADMA levels and diabetic nephropathy was shown in 408 patients with type 1 diabetes mellitus, 79 suggesting that ADMA may contribute to diabetes-induced end-organ damage. In non-diabetic subjects increased plasma ADMA levels are associated with insulin resistance. 80, 81 In contrast, in women with gestational diabetes increased plasma ADMA levels were not associated with insulin resistance. 82 This discrepancy might be explained by the fact that ADMA is directly associated with blood glucose levels, 81, 83 so that the association of ADMA and insulin resistance state may be modified in diabetes versus pre-diabetes. Table 1 gives an overview of published clinical studies on ADMA in diabetes mellitus and insulin resistance.
The benefit of intensive insulin therapy to normalize blood glucose in diabetes mellitus might also be explained by modulation of NO metabolism. In a rabbit model of prolonged critical illness, maintenance of normoglycaemia prevented excessive NO formation and preserved endothelial function, an effect that was paralleled by maintenance of normal ADMA plasma levels secondary to preserved DDAH activity. 84 Human data also support the notion that intensive insulin therapy modulates ADMA plasma concentration by Table 1 . Clinical studies of asymmetric dimethylarginine (ADMA) in patients with diabetes mellitus and related disorders.
Type 1 diabetes Subjects Results
Altinova et al. 78 -40 IDDM without vascular complications -35 healthy controls -ADMA was significantly higher in DM -L-Arginin and L-Arg/AMDA ratio were lower Tarnow et al. 79 -408 IDDM with overt diabetic nephropathy -192 IDDM with normoalbuminuria -ADMA increased in nephropathy patients with declining kidney function -ADMA was significantly higher in patients with major cardiovascular events -No significant relation between ADMA and other microvascular complications Marcovecchio et al. 85 -15 IDDM -ADMA, SDMA, arginine and ADMA/SDMA ratio decreased during hyperinsulinaemia -No correlation was found between insulin sensitivity and ADMA Heilman et al. 86 -30 children with IDDM -30 healthy children -ADMA and homocysteine were lower in IDDM -BP, hsCRP, ICAM-1, adiponectin levels were higher in IDDM Jehlicka et al. 87 -32 children with familial hypercholesterolaemia (FH) -30 children with IDDM -30 healthy controls -ADMA and oxLDL were higher in FH than in IDDM and healthy controls -IDDM had normal ADMA levels -ADMA levels remained the same after 3 months supplementation with folic acid Eid et al. 88 -32 men with untreated hypercholesterolaemia, 8 weeks of treatment with pravastatin/placebo -38 men with well-treated IDDM -20 healthy controls -ADMA levels were significantly higher and L-arginine/ ADMA ratio was significantly lower in IDDM and hypercholesterolaemia -Pravastatin had no effect on ADMA levels in hypercholesterolemic men Mittermayer et al. 89 -11 IDDM, four month aerobic exercise -15 healthy controls, no exercise -ADMA levels in IDDM were elevated at baseline -ADMA levels decreased after 2 and 4 months exercise to levels of healthy controls without exercise training Sibal et al. 30 -61 young IDDM -62 healthy controls -ADMA was significantly lower in IDDM -ICAM-1 was higher in IDDM -FMD was lower in IDDM
Insulin resistance
Eid et al. 90 -29 healthy subjects with borderline hypertension -ADMA and L-Arginine levels decreased during hyperinsulinaemia -Forearm blood flow (FBF) and NO-levels did not change -No correlation between ADMA and insulin/insulin resistance (baseline) Marliss et al. 91 -16 elderly subjects -15 obese subjects -18 lean subjects -ADMA was highest in obese subjects and slightly elevated in elderly -Endogenous protein flux was the strongest predictor of plasma ADMA followed by insulin sensitivity McLaughlin et al. 81 -10 obese women with insulin resistance (IR) -10 obese, insulin-sensitive (IS) women as controls -ADMA levels were higher in IR and decreased with weight loss -ADMA levels in IS did not change significantly -L-arginine/ADMA ratio was lower in IR and increased with weight loss while arginine levels remained similar. Perticone et al. 83 -63 hypertensive subjects -21 normotensive healthy subjects -ADMA and L-arginine were strongly associated with HOMA index (IS) in hypertensive patients, but not in normotensive patients -ADMA was an independent predictor of FBF und HOMA in the hypertensive group -HOMA was the only independent predictor of ADMA in the hypertensive group -Steady-state plasma glucose (SSPG as measure of IR), systolic blood pressure and triglycerides were significantly correlated with plasma ADMA -SSPG was more strongly correlated with ADMA than with insulin level and was the only statistically independent variable -After 3 months of treatment with rosiglitazone IS was improved and ADMA levels decreased, BP was unchanged -ADMA levels were not increased in hypertensives unless they showed IR Telejko et al. 92 -56 pregnant women with gestational diabetes -68 pregnant women with normal pregnancy -36 non-pregnant women as control -ADMA was highest in non-pregnant women and higher in women with gestational diabetes than in normal pregnancy -ADMA levels were correlated with fasting glucose and gestational age Mittermayer et al. 93 -77 women with gestational diabetes -follow up for up to 5 years after delivery -ADMA was the only independent predictor for deterioration of glucose tolerance after pregnancy with gestational diabetes
Type 2 diabetes
Böger et al. 75 -3,320 Framingham Offspring Study participants -out of these 372 NIDDM -ADMA levels in non-diabetic and diabetic subjects were similar -L-arginine/ADMA ratio was positively related to diabetes Hanai et al. 94 -225 NIDDM -out of these 183 normoalbuminuric -42 microalbuminuric -ADMA levels above median were associated with an increased risk of progression of nephropathy Ito et al. 95 -11 NIDDM without major diabetic complications or drug treatment for diabetes -8 healthy controls -4 weeks treatment with perindopril -Serum ADMA and vWF were elevated in patients with diabetes -ADMA decreased significantly after 4 weeks treatment with perindopril Asagami et al. 96 -31 patients with NIDDM in poor glycaemic control -out of these 16 treated with diet/metformin -15 treated with sulphonylurea/metformin.
-ADMA and fasting plasma glucose decreased similarly in both groups -Plasma L-arginine concentration in both groups remained the same Miyazaki et al. 97 -116 volunteers without symptoms of coronary or peripheral artery disease, -Among these 26 subjects with NIDDM -ADMA was positively correlated with age, mean arterial pressure and glucose tolerance -ADMA was significantly correlated to the IMT of the carotid artery Abbasi et al. 98 -16 NIDDM -18 controls -ADMA, plasma glucose, triglyceride levels were significantly higher in NIDDM -HDL was significantly lower -LDL and SDMA were similar Päivä et al. 99 -86 NIDDM -65 controls -ADMA and SDMA levels were lower in patients with diabetes -ADMA was inversely correlated with HbA1c -Plasma ADMA was not associated with hypercholesterolaemia and hypertension Xiong et al. 100 -25 NIDDM with macroangiopathy -25 NIDDM without macroangiopathy -40 controls -ADMA levels were increased in NIDDM -Patients with macroangiopathy had higher ADMA levels compared with patients without macroangiopathy -ADMA levels were not influenced by duration of diabetes
preserving DDAH activity. 107 An acute reduction of ADMA plasma levels by insulin was also demonstrated in 15 young patients with type 1 diabetes mellitus. 85 These findings from animal models and clinical studies lead to the suggestion that hyperglycaemia may increase plasma ADMA levels concomitantly with reduced ADMA metabolism by DDAH. However, they leave open the question of whether glucose itself or rather insulin is the agent that affects DDAH activity. In cultured endothelial cells hyperglycaemia-induced oxidative stress was associated with reduced DDAH activity, resulting in elevated ADMA concentrations in conditioned media and reduced NO formation. 108 In streptozotocin-induced diabetic rats, plasma ADMA levels were also increased as a result of reduced DDAH activity. 108 These effects are supported by the fact that mice overexpressing the human DDAH-1 showed decreased ADMA levels and improved insulin sensitivity compared with wild-type mice. 109 By contrast, no changes in ADMA plasma levels were observed in other experimental studies, [110] [111] but both studies show an attenuated L-arginine availability resulting in an attenuated NO-formation.
However, these conflicting results make it essential that we understand the mechanisms resulting in altered plasma ADMA levels and its role in diabetes mellitus to enable the development of novel therapeutic strategies.
The role of diabetes mellitus in the association of ADMA and disease: a hypothesis
An intriguing observation was made during our recent analysis of the association of ADMA plasma concentration and mortality risk in the population-based Framingham Offspring Devangelio et al. 101 -86 NIDDM -43 controls -ADMA levels were significantly higher in diabetic patients -No association to cholesterol, hypertension, smoking or diabetes duration -HbA1c and ADMA were directly correlated -Improvement in metabolic control resulted in a decrease in ADMA levels associated with a decrease in fasting blood glucose and HbA1c Konukoglu et al. 102 -35 with normal glucose tolerance -25 with intermediate glucose tolerance (IGT) -20 with diabetic glucose tolerance (DGT) -ADMA was highest at baseline in the DGT, and elevated in IGT -ADMA increased in all three groups after glucose challenge -There was a significant relationship between ADMA and inflammation and soluble adhesion markers Anderson et al. 103 -Patients undergoing angiography for clinical indication -355 with normal fasting glucose -239 with intermediate fasting glucose -256 with diabetes -ADMA strongly predicted glycaemic category -ADMA in the 4th quartile had a higher risk of death/myocardial infarction, which was independent of other risk factors
Makino et al. 104 -21 diabetic patients with diabetic retinopathy -18 uncomplicated diabetes -16 healthy controls -ADMA levels were elevated in patients with diabetic retinopathy -ADMA levels of uncomplicated diabetes and controls were similar Sugai et al. 105 -21 non-diabetic subjects -17 diabetic subjects -Measures obtained during cataract surgery -ADMA levels were higher in subjects with diabetes -Aqueous humour levels but not serum levels of ADMA correlated with HbA1c Yasuda et al. 106 -24 NIDDM with poor glycaemic control -Out of these 10 conventionally treated -14 intensive treatment -Fasting blood glucose, total and LDL cholesterol, TNFalpha, ADMA decreased significantly, flow-mediated vasodilation (FMD) improved in the intensive treatment group -HOMA, insulin, triglycerides and HDL did not change -FMD correlated inversely with TNFalpha, ADMA and fasting glucose -Intensive treatment of hyperglycaemia was associated with improvement of endothelial dysfunction and decrease in TNFalpha and ADMA levels cohort: whilst the mean ADMA levels in subjects with and without diabetes mellitus were virtually identical (0.55 µmol/l in subjects without diabetes versus 0.55 µmol/l in subjects with diabetes), we noted an effect modification of the association of ADMA with all-cause mortality by diabetes status. 75 Further analysis into this effect showed that in subjects without diabetes mellitus at baseline, increasing quartiles of ADMA were positively associated with mortality, whereas in subjects with diabetes mellitus there was a non-significant trend towards the opposite (Figure 2 ). This observation was corroborated by a preliminary evaluation of data from the Hoorn study, in which a similar intriguing finding among subjects with and without diabetes mellitus was reported, 112 with a significant positive association between quintiles of ADMA and mortality in subjects without diabetes, but a significant inverse relationship between quintiles of ADMA and mortality in subjects with diabetes. What may be the explanation for these opposite associations observed in people with and without diabetes? We speculate that uncoupling of eNOS in diabetes mellitus may be involved in this observation. eNOS has been shown to be uncoupled in diabetes, which means that the electron flow from NADPH to L-arginine and O 2 via the two subunits of the eNOS enzyme and its multiple co-factors is disturbed, resulting in the production of superoxide radicals (O 2 -) instead of NO and L-citrulline ( Figure 3 ). Uncoupling of eNOS is brought about by oxidative degradation of the essential NOS co-factor tetrahydrobiopterin, 113 an effect that can be measured after exposure of endothelial cells to high glucose levels. 114 Reduced availability of L-arginine 115 and low concentrations of NOS inhibitors such as L-NMMA 115 have also been demonstrated to cause eNOS uncoupling, and antioxidant treatment has been shown to restore endothelial function in diabetes mellitus. [117] [118] The role of ADMA in this context has been less well investigated so far. Structural similarity with L-NMMA suggests that ADMA may also cause eNOS uncoupling, and some experimental evidence for this hypothesis can be found. Superoxide production was increased in human umbilical vein endothelial cells (HUVEC) and isolated arterioles from rat gracilis muscle after incubation with ADMA. [119] [120] Moreover, elevated ADMA levels as a result of decreased DDAH activity in lipopolysaccharide (LPS)treated mice were accompanied by increased production of superoxide which was blocked by treatment with L-NMMA, indicating an uncoupled NOS as the source of superoxide. 121 Evidence from a clinical study in which elevated ADMA levels were correlated with increased NOS-derived production of reactive oxygen species (ROS) in the vasculature of patients undergoing coronary bypass surgery supports this idea; 119 however, definite proof for a causal relationship in diabetes mellitus is still lacking. Superoxide radicals produced by the uncoupled eNOS can exert detrimental effects either directly or by reacting with vascular NO to form the highly reactive peroxynitrite. Next to oxidative stress, nitrosative stress has been discussed as a potential mechanism involved in insulin resistance and other diseases, possibly by S-nitrosylation of signalling proteins (see Kaneki et al. 121 Hazard ratios for total mortality according to quartiles of asymmetric dimethylarginine (ADMA) in the Framingham Offspring study. Data were originally published in Böger et al. 75 In subjects from the general population who had no diabetes at baseline, ADMA was associated with an increasing risk of total mortality, whereas in subjects with diabetes at baseline, there was a non-significant trend towards lower risk of total mortality with increasing quartiles of ADMA.
acute lung injury in mice, Sharma et al. 121 demonstrated that the increased superoxide production by the uncoupled NOS resulted in increased formation of nitrated proteins due to elevated levels of peroxynitrite as well as increased lung permeability. In this model, treatment with the peroxynitrite scavengers uric acid and MnTymPyp was able to reduce protein nitrosylation and to attenuate lung permeability. 121 Moreover, oxidation of tetrahydrobiopterin by peroxynitrite contributes to the depletion of this essential NOS cofactor and so in turn promotes eNOS uncoupling. 123 Recently, endothelium-derived contracting factors (EDCF) have been discovered as another set of players in the vasculature. Among them, the most prominent are vasoconstrictor prostaglandins and their endoperoxide precursors. 124 In the context of ageing and vascular diseases, such as diabetes mellitus, with reduced bioavailability of NO and increased levels of superoxide, endothelial cells can produce EDCFs in a calcium-dependent way presumably via activation of phospholipase A 2 . 124 EDCFs activate the thomboxane-prostanoid (TP) receptors on vascular smooth muscle cells causing vasoconstriction. 124 Together with the above-mentioned mechanisms, this may even further impair endothelial function.
In the presence of uncoupled eNOS, any inhibition of this enzyme's activity will result in reduction of oxidative and nitrosative burden for the endothelium, and thus may be beneficial for vascular disease. In contrast, in subjects with normally functioning, i.e. NO-generating, eNOS, any inhibition of the enzyme's activity will result in reduced NO generation, and thus be detrimental for vascular disease. We, therefore, propose that eNOS uncoupling may underlie the paradoxical association of ADMA with mortality in subjects with uncomplicated diabetes mellitus. It is possible that in patients with advanced stages of diabetes mellitus and diabetic complications, ADMA may emerge as a prognostic marker positively associated with risk like in other atherosclerotic vascular diseases. This could be caused by changes in the relative contribution of hyperglycaemia, other traditional cardiovascular risk factors, ADMA, and oxidative stress to the progression of vascular diseases in later stages of the disease. Such stage-dependent association of ADMA with diabetic vascular complications might also explain the discrepant findings for ADMA in early and more advanced diabetes mellitus that have already been reported in the literature from cross-sectional studies, as discussed above. 
